The Pharmagellan Guide to Biotech Forecasting and Valuation

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser—or aspire to be one—then you need to build and analyze forecasts and valuations of R&D-stage drugs. This book is for you.

"Deserves a spot on the bookshelf of every biotech CFO." — Bruce Booth, Partner, Atlas Venture
"A helpful and insightful resource for anyone who finds themselves staring at a blank Excel spreadsheet." — Adam Feuerstein, Senior Columnist, TheStreet.com
"This is the book I wish I'd had when I started out." — Vin Milano, CEO, Idera Pharmaceuticals
"Invaluable, rigorously detailed, and well validated." — John Sullivan, Director of Equity Research, Leerink Partners

The Pharmagellan Guide to Biotech Forecasting and Valuation is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage assets and companies.

• Vetted benchmarks for key drivers of income, expenses, and valuation.
• Proprietary analyses by Pharmagellan's experienced consulting team.
• Over 150 current references from peer-reviewed research, industry white papers, and SEC filings.
• Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.